CD55 and cancer: In this study, we hypothesized that breaking the symmetry of an antibody improved CDC and that its cancer cell-killing effect was synergistically enhanced by formulating a bispecific antibody targeting CD55, an immune checkpoint inhibitor of the complement cascade in the human immune system.